Prof. Jorge D. Erusalimsky
||Cardiff School of Health Sciences
Cardiff Metropolitan University
Tel: + 44 (0) 29 2041 6853
Fax: + 44 (0) 29 2041 6982
Since 2006: Professor of Biomedical Sciences and Head of the Cellular Senescence and Vascular Biology Group
, Cardiff School of Health Sciences, Cardiff Metropolitan University, Cardiff, UK
Hon. Professor of University College London, London, UK
Since 2007: Research Coordinator, Centre for Biomedical Research, Cardiff School of Health Sciences, Cardiff Metropolitan University, Cardiff, UK
2004 - 2006 Reader in Cell and Molecular Biology, The Wolfson Institute for Biomedical Research, University College London, UK
1996 - 2003 Senior Lecturer, Department of Medicine, University College London, UK
1991 -1995 Lecturer, Department of Medicine, King's College School of Medicine and Dentistry, London, UK
1987 - 1991 Post-doctoral Research Fellow with Dr. Enrique Rozengurt, Imperial Cancer Research Fund, London, UK
1985 - 1987 Post-doctoral Research Fellow with Dr. Cesar Milstein, Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
1983 - 1984 Post-doctoral Research Fellow with Prof. Z. Selinger, Department of Biological Chemistry, Hebrew University, Jerusalem, Israel
1983 PhD, Hebrew University, Jerusalem, Israel
1977 BSc, Hebrew University, Jerusalem, Israel
Jorge Erusalimsky has been carrying out research on the cellular and molecular mechanisms that underlie the relationship between ageing and cardiovascular diseases for over fifteen years. His work in this area was among the first to demonstrate the occurrence of vascular cell senescence in vivo. He has also investigated the roles that telomere integrity, telomerase activity, oxidative stress and growth factors play in the control of endothelial cell replicative capacity. His current research in this area focuses on the modulation of vascular cell senescence by stress-response proteins and on biomarkers of vascular ageing. In addition, Prof. Erusalimsky has a long standing interest in megakaryocytopoiesis and platelet biogenesis. He has published more than sixty peer-reviewed articles.
See Research of the Cellular Senescence and Vascular Biology Group
In the area of ageing, cellular senescence and cardiovascular disease
1. Kurz D.J., Decary S., Hong Y. and Erusalimsky J.D. (2000) Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Science 113, 3613-3622.
2. Fenton M., Barker S., Kurz D.J. and Erusalimsky J.D. (2001) Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler. Thromb. Vasc. Biol. 21, 220-226.
3. Moncada S. and Erusalimsky J.D. (2002) Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nature Reviews Mol. Cell Biol. 3, 214-220.
4. Kurz D.J., Hong Y., Trivier E., Huang H-L, Decary S., Zang G., Lüscher T.F. and Erusalimsky J.D. (2003) Fibroblast growth factor-2, but not vascular endothelial growth factor, up-regulates telomerase activity in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23, 748-754.
5. Kurz D.J., Decary S., Hong Y., Trivier, E., Akhmedov, A and Erusalimsky J.D. (2004) Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J. Cell Sci. 117, 2417-2426.
6. Erusalimsky J.D. and Kurz D.J. (2005) Cellular senescence in vivo: Its relevance in ageing and cardiovascular disease. Exp. Gerontol. 40, 634-642.
7. Erusalimsky J.D. and Kurz D.J. (2006) Endothelial cell senescence. In Handbook of Experimental Pharmacology, vol. 176 (Pt2), The Vascular Endothelium (Moncada, S. and Higgs, A., eds). Springer Verlag, pp 213-248.
8. Hong Y., Quintero M., Frakich N.M., Trivier E. and Erusalimsky, J.D. (2007) Evidence against the involvement of nitric oxide in the modulation of telomerase activity or replicative capacity of human endothelial cells. Exp. Gerontol. 42, 904-910
9. Erusalimsky J.D. and Moncada, S. (2007) Nitric oxide and mitochondrial signaling: From Physiology to Pathophysiology. Arterioscler. Thromb. Vasc. Biol. 27, 2524-2531.
10. Erusalimsky J.D. (2009) Vascular endothelial senescence: From mechanisms to pathophysiology. J. Appl. Physiol. 106, 326-332.
11. Debacq-Chainiaux F., Erusalimsky J.D., Campisi J. and Toussaint O. (2009) Methods to detect senescence-associated β-galactosidase (SA- βGAL) activity, a biomarker of senescent cells in culture and in vivo. Nature Protoc. 4, 1798-1806.
12. Steptoe A., Hamer M., Butcher L., Lin J., Brydon L., Kivimaki M., Marmot M., Blackburn E. and Erusalimsky J.D. (2011) Educational attainment but not current socioeconomic status is associated with leukocyte telomere length. Brain Behav. Immun. 25, 1292-1298.
13. Brydon L., Lin J., Butcher L., Hamer M., Erusalimsky J.D., Blackburn E.H. and Steptoe A. (2012) Hostility and cellular aging in men from the Whitehall II cohort Biol. Psychiatry. 71, 767-773.
14. Jackowska M., Hamer M., Carvalho L., Erusalimsky J.D., Butcher L. and Steptoe A. (2012) Short sleep duration is associated with shorter telomere length in healthy men: Findings from the Whitehall II cohort study. PLoS ONE 7, e47292.
15. Cardus A., Uryga A., Walters G. and Erusalimsky J.D. (2012) SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction and senescence. Cardiovasc. Res. Doi:10.1093/cvr/cvs352 First published on line: December 1, 2012.
In the area of megakaryocytopoiesis
1. Hong Y., Dumènil D., van der Loo B., Goncalves F., Vainchenker W. and Erusalimsky J.D. (1998) Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl expressing UT-7 cells. Blood 91, 1-11.
2. Cotton J.M., Hong Y., Hawe E., Mathur A., Humphries S.E., Brown A.S., Martin J.F. and Erusalimsky J.D. (2003) Rise of circulating thrombopoietin following cardiothoracic surgery is potentiated in patients with coronary atherosclerosis: correlation with a preceding increase in levels of interleukin-6. Thromb. Haemost. 89, 538-543.
3. Mathur A., Hong Y. Wang G. and Erusalimsky J.D. (2004) Assays of megakaryocyte development: surface antigen expression, ploidy and size. Methods Mol. Biol. 272, 309-322.
4. Wang G., Franklin R., Hong Y. and Erusalimsky J.D. (2005) Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Brit. J. Pharmacol. 146, 324-332.
5. Hong Y., Wang G., Gutierrez del Arroyo A., Hernandez J., Skene C. and Erusalimsky J.D. (2006) Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: Selectivity of anagrelide for the megakaryocytic lineage. Leukemia 20, 1117-1122.
6. Ahluwalia M., Donovan H., Singh N., Butcher L. and Erusalimsky J.D. (2010) Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction. J. Thromb. Haemost. 8, 2252-2261.